The New England Comparative Effectiveness Public Advisory Council (New England CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. The New England CEPAC convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the New England CEPAC process, and find out how topics are selected.
New England CEPAC directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the New England CEPAC must meet ICER’s criteria for Conflict of Interest.
The box below provides information on the topic of the next meeting of the New England CEPAC. For more information about past and other upcoming meetings, see the box to the right.
2345 Commonwealth Avenue
Newton, MA 02466
The New England CEPAC will convene to review ICER's evidence report assessing the clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder related to prolonged use of antipsychotic medications.
Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals there are no other effective treatment options, and symptoms can persist after discontinuing or changing antipsychotic therapy.
Interventions of Interest:
- Valbenazine (IngrezzaTM, Neurocrine Biosciences, Inc)
- Deutetrabenazine (AustedoTM, Teva)
- Tetrabenazine (Xenazine®)
Date of Review: December 2017View materials